$ANIK
Anika Therapeutics, Inc.

2012 Q4 Form 10-K Financial Statement

#000115752313001397 Filed on March 14, 2013

View on sec.gov

Income Statement

Concept 2012 Q4 2012 Q3 2012 Q2
Revenue $22.61M $14.77M $19.62M
YoY Change 22.57% -19.99% 21.58%
Cost Of Revenue $7.270M $7.221M $8.084M
YoY Change 1.98% -2.35% 21.46%
Gross Profit $14.19M $6.834M $10.80M
YoY Change 33.9% -34.04% 23.28%
Gross Profit Margin 62.77% 46.28% 55.02%
Selling, General & Admin $3.670M $3.602M $4.109M
YoY Change -24.64% -23.57% -2.95%
% of Gross Profit 25.86% 52.7% 38.05%
Research & Development $1.340M $1.217M $1.298M
YoY Change -12.42% -20.52% -17.53%
% of Gross Profit 9.44% 17.81% 12.02%
Depreciation & Amortization $1.170M $1.180M $1.190M
YoY Change 10.38% 18.0% 16.67%
% of Gross Profit 8.25% 17.27% 11.02%
Operating Expenses $5.000M $4.819M $5.407M
YoY Change -21.87% -22.82% -6.9%
Operating Profit $9.189M $2.727M $6.134M
YoY Change 118.94% -43.4% 66.79%
Interest Expense -$40.00K -$45.16K -$49.13K
YoY Change -20.0% -2.39% 8.5%
% of Operating Profit -0.44% -1.66% -0.8%
Other Income/Expense, Net
YoY Change
Pretax Income $7.750M $2.682M $6.085M
YoY Change 59.14% -43.79% 67.52%
Income Tax $3.290M $1.036M $2.348M
% Of Pretax Income 42.45% 38.65% 38.59%
Net Earnings $4.463M $1.645M $3.737M
YoY Change 54.81% -44.73% 63.71%
Net Earnings / Revenue 19.74% 11.14% 19.04%
Basic Earnings Per Share $0.33 $0.12 $0.28
Diluted Earnings Per Share $0.31 $0.11 $0.26
COMMON SHARES
Basic Shares Outstanding 13.32M shares 13.29M shares 13.26M shares
Diluted Shares Outstanding 14.30M shares 14.46M shares 14.44M shares

Balance Sheet

Concept 2012 Q4 2012 Q3 2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $44.10M $39.90M $37.90M
YoY Change 23.18% 37.59% 41.42%
Cash & Equivalents $44.07M $39.86M $37.91M
Short-Term Investments
Other Short-Term Assets $3.500M $3.300M $3.200M
YoY Change -5.41% -17.5% -28.89%
Inventory $8.283M $8.932M $10.78M
Prepaid Expenses
Receivables $21.46M $16.34M $17.69M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $77.38M $68.40M $69.60M
YoY Change 20.65% 16.73% 21.04%
LONG-TERM ASSETS
Property, Plant & Equipment $35.11M $35.94M $36.42M
YoY Change -3.72% -2.08% -1.3%
Goodwill $9.066M $8.819M $8.628M
YoY Change 2.05%
Intangibles $20.33M $21.46M $21.51M
YoY Change -12.16%
Long-Term Investments
YoY Change
Other Assets $200.0K $200.0K $200.0K
YoY Change 0.0% -33.33% -50.0%
Total Long-Term Assets $64.68M $66.47M $66.78M
YoY Change -5.85% -6.64% -9.64%
TOTAL ASSETS
Total Short-Term Assets $77.38M $68.40M $69.60M
Total Long-Term Assets $64.68M $66.47M $66.78M
Total Assets $142.1M $134.9M $136.4M
YoY Change 6.94% 3.91% 3.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.342M $1.908M $3.941M
YoY Change -45.53% -49.8% -48.14%
Accrued Expenses $5.837M $4.389M $4.276M
YoY Change 9.69% -20.2% -22.26%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.600M $1.600M $1.600M
YoY Change 0.0% 0.0% 0.0%
Total Short-Term Liabilities $14.45M $12.15M $15.21M
YoY Change -0.59% -19.5% -12.56%
LONG-TERM LIABILITIES
Long-Term Debt $8.000M $8.400M $8.800M
YoY Change -16.67% -16.0% -15.38%
Other Long-Term Liabilities $1.541M $1.539M $1.535M
YoY Change -0.49% -68.59% -76.01%
Total Long-Term Liabilities $9.541M $9.939M $10.34M
YoY Change -14.42% -33.29% -38.48%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.45M $12.15M $15.21M
Total Long-Term Liabilities $9.541M $9.939M $10.34M
Total Liabilities $23.99M $22.09M $25.55M
YoY Change -6.59% -40.12% -36.6%
SHAREHOLDERS EQUITY
Retained Earnings $46.01M $41.55M $39.90M
YoY Change 34.33%
Common Stock $138.7K $138.0K $137.7K
YoY Change 1.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $108.9M $103.5M $100.7M
YoY Change
Total Liabilities & Shareholders Equity $142.1M $134.9M $136.4M
YoY Change 6.94% 3.91% 3.79%

Cashflow Statement

Concept 2012 Q4 2012 Q3 2012 Q2
OPERATING ACTIVITIES
Net Income $4.463M $1.645M $3.737M
YoY Change 54.81% -44.73% 63.71%
Depreciation, Depletion And Amortization $1.170M $1.180M $1.190M
YoY Change 10.38% 18.0% 16.67%
Cash From Operating Activities $4.810M $2.210M $5.220M
YoY Change -34.11% -25.84% -472.86%
INVESTING ACTIVITIES
Capital Expenditures -$210.0K -$140.0K -$930.0K
YoY Change -53.33% -51.72% 60.34%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$210.0K -$140.0K -$930.0K
YoY Change -53.33% -51.72% 60.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -350.0K -160.0K -360.0K
YoY Change 191.67% -60.0% 28.57%
NET CHANGE
Cash From Operating Activities 4.810M 2.210M 5.220M
Cash From Investing Activities -210.0K -140.0K -930.0K
Cash From Financing Activities -350.0K -160.0K -360.0K
Net Change In Cash 4.250M 1.910M 3.930M
YoY Change -36.85% -16.59% -273.89%
FREE CASH FLOW
Cash From Operating Activities $4.810M $2.210M $5.220M
Capital Expenditures -$210.0K -$140.0K -$930.0K
Free Cash Flow $5.020M $2.350M $6.150M
YoY Change -35.23% -28.13% -850.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13919215 shares
CY2009Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2350000 shares
CY2011Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
3150000 shares
CY2012Q2 dei Entity Public Float
EntityPublicFloat
187079886
CY2003Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1500000 shares
CY2008Q4 us-gaap Deferred Finance Costs Ownshare Lending Arrangement Issuance Costs Net
DeferredFinanceCostsOwnshareLendingArrangementIssuanceCostsNet
171000
CY2009Q4 us-gaap Area Of Land
AreaOfLand
26000 sqft
CY2009Q4 us-gaap Stockholders Equity
StockholdersEquity
82143502
CY2009Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
40900
CY2009Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24426990
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
85190146
CY2010Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
37428
CY2010Q4 us-gaap Sales Revenue Goods Net Percentage
SalesRevenueGoodsNetPercentage
1.000 pure
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28201932
CY2010Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
30000
CY2010Q4 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsOutstandingNumber
1625253 shares
CY2010Q4 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageExercisePrice
6.92
CY2011Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1831127
CY2011Q4 us-gaap Goodwill
Goodwill
8883407
CY2011Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
50850630
CY2011Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
1918926
CY2011Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
7375141
CY2011Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
1839924
CY2011Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
17307786
CY2011Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2866667
CY2011Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1548652
CY2011Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1250000 shares
CY2011Q4 us-gaap Sales Revenue Goods Net Percentage
SalesRevenueGoodsNetPercentage
1.000 pure
CY2011Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
695914
CY2011Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
34252221
CY2011Q4 us-gaap Assets
Assets
132844434
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
94762778
CY2011Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
10429816
CY2011Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2011Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
27159066
CY2011Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1172196
CY2011Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
2072931
CY2011Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-3067181
CY2011Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000 shares
CY2011Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
450482
CY2011Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
12805504
CY2011Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13630607 shares
CY2011Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
793430
CY2011Q4 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
800000
CY2011Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1496910
CY2011Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1503565
CY2011Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4299680
CY2011Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
56170
CY2011Q4 us-gaap Inventory Net
InventoryNet
7302483
CY2011Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
825884
CY2011Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
132844434
CY2011Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
12421398
CY2011Q4 us-gaap Long Term Debt
LongTermDebt
11200000
CY2011Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssets
7594729
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35777222
CY2011Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13630607 shares
CY2011Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
23148563
CY2011Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5321594
CY2011Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
4091366
CY2011Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
840350
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14538423
CY2011Q4 us-gaap Deferred Revenue
DeferredRevenue
7886107
CY2011Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
334473
CY2011Q4 us-gaap Common Stock Value
CommonStockValue
136305
CY2011Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2011Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
5019440
CY2011Q4 us-gaap Assets Current
AssetsCurrent
64137544
CY2011Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1707552
CY2011Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2011Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
7349289
CY2011Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2011Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2011Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
417726
CY2011Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
14380752
CY2011Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
2366412
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
36469878
CY2011Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1600000
CY2011Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
63441433
CY2011Q4 us-gaap Inventory Adjustments
InventoryAdjustments
1375150
CY2011Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9600000
CY2011Q4 anik Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
205042
CY2011Q4 anik Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
5210775
CY2011Q4 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsOutstandingIntrinsicValue
6107869
CY2011Q4 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsOutstandingNumber
2108003 shares
CY2011Q4 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsGrantsInPeriodWeightedAverageExercisePrice
6.98
CY2011Q4 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsForfeituresInPeriodWeightedAverageExercisePrice
6.41
CY2011Q4 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageExercisePrice
7.26
CY2011Q4 anik Accrued Research Grants Current
AccruedResearchGrantsCurrent
989556
CY2011Q4 anik Percentage Of Significant Customer Balances To Total Accounts Receivable
PercentageOfSignificantCustomerBalancesToTotalAccountsReceivable
0.58 pure
CY2011Q4 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Vested Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsVestedAggregateIntrinsicValue
2390591
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1539477
CY2012Q4 us-gaap Goodwill
Goodwill
9065891
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1519613
CY2012Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
1600000
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
52376013
CY2012Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
2031583
CY2012Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
6400000
CY2012Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
2000000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
108925134
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
971500
CY2012Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
22863921
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1826000
CY2012Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
42270
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1569862
CY2012Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
1988509
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-2654630
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000 shares
CY2012Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
2000000
CY2012Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1798669
CY2012Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
12613877
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13866060 shares
CY2012Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
642853
CY2012Q4 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
700000
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1461305
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1584583
CY2012Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
777056
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1484015
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2341838
CY2012Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
56170
CY2012Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
2000000
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2875067
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1541124
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1250000 shares
CY2012Q4 us-gaap Sales Revenue Goods Net Percentage
SalesRevenueGoodsNetPercentage
1.000 pure
CY2012Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
194364
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
46009681
CY2012Q4 us-gaap Assets
Assets
142069051
CY2012Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
6997397
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
2520746
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
21462481
CY2012Q4 us-gaap Inventory Net
InventoryNet
8283472
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
954559
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
142069051
CY2012Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
28195345
CY2012Q4 us-gaap Long Term Debt
LongTermDebt
9600000
CY2012Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssets
6482404
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44067477
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13866060 shares
CY2012Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
20334636
CY2012Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
1600000
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5837044
CY2012Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
6109807
CY2012Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
1274477
CY2012Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
2000000
CY2012Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
2000000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14452618
CY2012Q4 us-gaap Deferred Revenue
DeferredRevenue
5027845
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
138659
CY2012Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
337459
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1793685 shares
CY2012Q4 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsOutstandingIntrinsicValue
4074471
CY2012Q4 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
4000000
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
6400000
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2152778
CY2012Q4 us-gaap Assets Current
AssetsCurrent
77384490
CY2012Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1396609
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2012Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
7648063
CY2012Q4 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsVestedAndExpectedToVestOutstandingNumber
1763000 shares
CY2012Q4 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsOutstandingNumber
1793685 shares
CY2012Q4 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
8.56
CY2012Q4 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsGrantsInPeriodWeightedAverageExercisePrice
12.06
CY2012Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
933732
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
405302
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
11265433
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
17263032
CY2012Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
2477833
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
35112981
CY2012Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1600000
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
65431424
CY2012Q4 us-gaap Inventory Adjustments
InventoryAdjustments
1161805
CY2012Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
8000000
CY2012Q4 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Vested And Expected To Vest Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm
P4Y7M17D
CY2012Q4 anik Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
171053
CY2012Q4 anik Operating Leases Future Minimum Payments Due In Five Years And Thereafter
OperatingLeasesFutureMinimumPaymentsDueInFiveYearsAndThereafter
5829000
CY2012Q4 anik Intangible Assets Accumulated Amortization
IntangibleAssetsAccumulatedAmortization
6169688
CY2012Q4 anik Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
6131473
CY2012Q4 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsForfeituresInPeriodWeightedAverageExercisePrice
6.58
CY2012Q4 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageExercisePrice
8.30
CY2012Q4 anik Intangible Assets Gross Carrying Amount
IntangibleAssetsGrossCarryingAmount
30098000
CY2012Q4 anik Accrued Research Grants Current
AccruedResearchGrantsCurrent
110350
CY2012Q4 anik Percentage Of Significant Customer Balances To Total Accounts Receivable
PercentageOfSignificantCustomerBalancesToTotalAccountsReceivable
0.78 pure
CY2012Q4 anik Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
102414
CY2012Q4 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Vested Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsVestedAggregateIntrinsicValue
2115267
CY2009Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
850000 shares
CY2011Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
800000 shares
CY2009 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
74000
CY2010 us-gaap Costs And Expenses
CostsAndExpenses
48018908
CY2010 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
105300
CY2010 us-gaap Operating Income Loss
OperatingIncomeLoss
7537686
CY2010 us-gaap Amortization Of Acquired Intangible Assets
AmortizationOfAcquiredIntangibleAssets
2011639
CY2010 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
197246
CY2010 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
7853461
CY2010 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2679677
CY2010 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
52735730
CY2010 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5784731
CY2010 us-gaap Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities
EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities
-0.021 pure
CY2010 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1600000
CY2010 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.022 pure
CY2010 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1102369
CY2010 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1768219
CY2010 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
1056921
CY2010 us-gaap Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
-21188
CY2010 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2010 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3320352
CY2010 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0111 pure
CY2010 us-gaap Share Based Compensation
ShareBasedCompensation
1102617
CY2010 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.32
CY2010 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-158028
CY2010 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
2828029
CY2010 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
302723
CY2010 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Foreign
EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
0.026 pure
CY2010 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-4601729
CY2010 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.025 pure
CY2010 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
37810
CY2010 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
1063841
CY2010 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Investment
EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment
-0.008 pure
CY2010 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.412 pure
CY2010 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y
CY2010 us-gaap Income Taxes Paid
IncomeTaxesPaid
360000
CY2010 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
479529
CY2010 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2751468
CY2010 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.078 pure
CY2010 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2784977
CY2010 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3774942
CY2010 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-28239
CY2010 us-gaap Inventory Write Down
InventoryWriteDown
699057
CY2010 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-445650
CY2010 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13646533 shares
CY2010 us-gaap Sales Revenue Net
SalesRevenueNet
55556594
CY2010 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3716478
CY2010 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2547776
CY2010 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-194620
CY2010 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6874633
CY2010 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1337320
CY2010 us-gaap Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends
IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends
20630 shares
CY2010 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2547776
CY2010 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.34
CY2010 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.5760 pure
CY2010 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
11944795
CY2010 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12624495 shares
CY2010 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1220359
CY2010 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-6920
CY2010 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1022038 shares
CY2010 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2010 us-gaap Cost Of Goods Sold
CostOfGoodsSold
23826604
CY2010 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
2820864
CY2010 us-gaap Depreciation
Depreciation
1308713
CY2010 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1102617
CY2010 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
7343066
CY2010 us-gaap Allowance For Doubtful Accounts Receivable Charge Offs
AllowanceForDoubtfulAccountsReceivableChargeOffs
301984
CY2010 us-gaap Interest Paid
InterestPaid
222919
CY2010 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
291107
CY2010 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
1953946
CY2010 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0188 pure
CY2010 us-gaap Tax Benefit From Stock Options Exercised1
TaxBenefitFromStockOptionsExercised1
-65434
CY2010 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1210970 shares
CY2010 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-1337408
CY2010 us-gaap Net Income Loss
NetIncomeLoss
4315995
CY2010 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
65434
CY2010 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-7698
CY2010 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
17317671
CY2010 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2888277
CY2010 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3027071
CY2010 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-61522
CY2010 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
3089
CY2010 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
197244
CY2010 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2188082
CY2010 anik Share Based Compensation Tax Expense Benefit
ShareBasedCompensationTaxExpenseBenefit
244746
CY2010 anik Windfall Shortfall Tax Impacts To Equity
WindfallShortfallTaxImpactsToEquity
21000
CY2010 anik Allowance For Doubtful Accounts Provisions
AllowanceForDoubtfulAccountsProvisions
302723
CY2010 anik Percentage Of Net Revenue
PercentageOfNetRevenue
1.000 pure
CY2010 anik Percentage Of Revenue Accounted By Customers
PercentageOfRevenueAccountedByCustomers
0.805 pure
CY2010 anik Net Deferred Income Tax Expense Benefit
NetDeferredIncomeTaxExpenseBenefit
1970150
CY2010 anik Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
37427
CY2011 us-gaap Costs And Expenses
CostsAndExpenses
50811233
CY2011 us-gaap Operating Income Loss
OperatingIncomeLoss
13967402
CY2011 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
61956386
CY2011 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-6594292
CY2011 us-gaap Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities
EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities
-0.023 pure
CY2011 us-gaap Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
274190
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2011 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4002391
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0110 pure
CY2011 us-gaap Share Based Compensation
ShareBasedCompensation
1190697
CY2011 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.62
CY2011 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
38329
CY2011 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1600000
CY2011 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.009 pure
CY2011 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1190697
CY2011 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
7947275
CY2011 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
3574107
CY2011 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-568
CY2011 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
1907408
CY2011 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
331528
CY2011 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Foreign
EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
0.009 pure
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-2177978
CY2011 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.004 pure
CY2011 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
3327626
CY2011 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Investment
EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment
-0.002 pure
CY2011 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.386 pure
CY2011 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y
CY2011 us-gaap Amortization Of Acquired Intangible Assets
AmortizationOfAcquiredIntangibleAssets
2186203
CY2011 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
160470
CY2011 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
10173134
CY2011 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1400348
CY2011 us-gaap Income Taxes Paid
IncomeTaxesPaid
2651212
CY2011 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
570869
CY2011 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-213888
CY2011 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.057 pure
CY2011 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1400348
CY2011 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
7575290
CY2011 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-179939
CY2011 us-gaap Inventory Write Down
InventoryWriteDown
1427862
CY2011 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-947263
CY2011 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13747813 shares
CY2011 us-gaap Sales Revenue Net
SalesRevenueNet
64778635
CY2011 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2998037
CY2011 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-519405
CY2011 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-519405
CY2011 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.65
CY2011 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6168937
CY2011 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1165340
CY2011 us-gaap Cost Of Goods Sold
CostOfGoodsSold
26783738
CY2011 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
2822249
CY2011 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
90626
CY2011 us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
160470
CY2011 us-gaap Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends
IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends
59196 shares
CY2011 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-182388
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.5760 pure
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
15962992
CY2011 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13064051 shares
CY2011 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-224714
CY2011 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
155855
CY2011 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
683762 shares
CY2011 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2011 us-gaap Depreciation
Depreciation
1816188
CY2011 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1190697
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
13785014
CY2011 us-gaap Allowance For Doubtful Accounts Receivable Charge Offs
AllowanceForDoubtfulAccountsReceivableChargeOffs
2047
CY2011 us-gaap Interest Paid
InterestPaid
193880
CY2011 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
279816
CY2011 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
1989708
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0151 pure
CY2011 us-gaap Tax Benefit From Stock Options Exercised1
TaxBenefitFromStockOptionsExercised1
-274190
CY2011 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1142840 shares
CY2011 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-734050
CY2011 us-gaap Net Income Loss
NetIncomeLoss
8466680
CY2011 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
274190
CY2011 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-623093
CY2011 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
17858558
CY2011 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
3479632
CY2011 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5318334
CY2011 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-32156
CY2011 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
160470
CY2011 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1042845
CY2011 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
450482
CY2011 anik Share Based Compensation Tax Expense Benefit
ShareBasedCompensationTaxExpenseBenefit
219626
CY2011 anik Windfall Shortfall Tax Impacts To Equity
WindfallShortfallTaxImpactsToEquity
274000
CY2011 anik Allowance For Doubtful Accounts Provisions
AllowanceForDoubtfulAccountsProvisions
306520
CY2011 anik Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Exercises In Period Total Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsExercisesInPeriodTotalIntrinsicValue
679401
CY2011 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsGrantsInPeriod
679000 shares
CY2011 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsExercisesInPeriod
121188 shares
CY2011 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsForfeituresInPeriod
74187 shares
CY2011 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsExercisesInPeriodWeightedAverageExercisePrice
1.60
CY2011 anik Percentage Of Net Revenue
PercentageOfNetRevenue
1.000 pure
CY2011 anik Percentage Of Revenue Accounted By Customers
PercentageOfRevenueAccountedByCustomers
0.738 pure
CY2011 anik Net Deferred Income Tax Expense Benefit
NetDeferredIncomeTaxExpenseBenefit
1744227
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
3736868
CY2011 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Vested In Period Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsVestedInPeriodFairValue
774648
CY2011 anik Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
-19587
CY2011 anik Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Expirations In Period
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsExpirationsInPeriod
875 shares
CY2011 anik Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Expirations In Period Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsExpirationsInPeriodWeightedAverageExercisePrice
3.04
CY2012 dei Trading Symbol
TradingSymbol
ANIK
CY2012 dei Entity Registrant Name
EntityRegistrantName
ANIKA THERAPEUTICS INC
CY2012 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2012 dei Amendment Flag
AmendmentFlag
false
CY2012 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2012 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2012 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2012 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
CY2012 dei Document Type
DocumentType
10-K
CY2012 dei Document Period End Date
DocumentPeriodEndDate
2012-12-31
CY2012 dei Entity Central Index Key
EntityCentralIndexKey
0000898437
CY2012 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2012 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2012 us-gaap Costs And Expenses
CostsAndExpenses
51643307
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
19715198
CY2012 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
68010169
CY2012 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2879330
CY2011Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
17756000
CY2012 us-gaap Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities
EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities
-0.036 pure
CY2012 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1600000
CY2012 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.009 pure
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1151199
CY2012 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
12170011
CY2012 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
8291595
CY2012 us-gaap Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
452471
CY2012 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-17033
CY2012 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
776486
CY2012 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
135353
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2011Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.22
CY2011Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13765533 shares
CY2012Q4 us-gaap Asset Impairment Charges
AssetImpairmentCharges
1600000
CY2012Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.31
CY2012 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4525247
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0063 pure
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
1151199
CY2012 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.82
CY2012 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Foreign
EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
0.025 pure
CY2012 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
1604256
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-6642892
CY2012 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal"> Concentration of Credit Risk and Significant Customers</font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div> <div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal"> The Company has no significant off-balance sheet risks related to foreign exchange contracts, option contracts or other foreign hedging arrangements. The Company currently maintains its cash equivalent balance with one major international financial institution.</font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#xA0;</font></div> <div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal"> The Company, by policy, routinely assesses the financial strength of its customers. As a result, the Company believes that its accounts receivable credit risk exposure is limited.</font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#xA0;</font></div> <div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal"> &#xA0;As of December&#xA0;31, 2012, DePuy Mitek, Inc., Medtronic Xomed, Soylu Medikal San ve Dis Tic Ltd., Rivex Pharma, and Takeda/Nycomed/Biomeks, combined, represented 78% of the Company&#x2019;s accounts receivable balance.&#xA0;&#xA0;As of December&#xA0;31, 2011, DePuy Mitek, Inc., Bausch and Lomb,&#xA0;Medtronic Xomed, Azienda USL Roma, and A.T. Grade, combined, represented 58% of the Company&#x2019;s accounts receivable balance.</font></div> </div>
CY2011Q3 us-gaap Sales Revenue Net
SalesRevenueNet
18455817
CY2011Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.23
CY2011Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12817910 shares
CY2012Q4 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
2500000
CY2012Q4 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
300000
CY2012 us-gaap Nature Of Operations
NatureOfOperations
<div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> 1. Business</font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div> <div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal"> Anika Therapeutics,&#xA0;Inc. (&#x201C;Anika,&#x201D; the &#x201C;Company,&#x201D; &#x201C;we,&#x201D; &#x201C;us,&#x201D; or &#x201C;our&#x201D;) develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair.&#xA0;These products are based on hyaluronic acid (&#x201C;HA&#x201D;), a naturally occurring, biocompatible polymer found throughout the body. Due to its unique biophysical and biochemical properties, HA plays an important role in a number of physiological functions such as the protection and lubrication of soft tissues and joints, the maintenance of the structural integrity of tissues, and the transport of molecules to and within cells.</font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal"> &#xA0;&#xA0;</font></div> <div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal"> The Company is subject to risks common to companies in the biotechnology and medical device industries including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with FDA and foreign regulations and approval requirements as well as the ability to grow the Company&#x2019;s business.</font></div> </div>
CY2012 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.012 pure
CY2012 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
38329
CY2012 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
7594287
CY2012 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Investment
EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment
-0.002 pure
CY2012 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.398 pure
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y
CY2012 us-gaap Amortization Of Acquired Intangible Assets
AmortizationOfAcquiredIntangibleAssets
2028498
CY2012 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
388675
CY2012 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
10548677
CY2012 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1504707
CY2012 us-gaap Income Taxes Paid
IncomeTaxesPaid
6496000
CY2012 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
602447
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5388036
CY2011Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
7394922
CY2012 us-gaap Revenue Recognition Services Licensing Fees
RevenueRecognitionServicesLicensingFees
<div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal"> Licensing, Milestone and Contract Revenue</font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#xA0;</div> <div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal"> Licensing, milestone, and contract revenue consist of revenue recognized on initial and milestone payments, as well as contractual amounts received from partners. The Company&#x2019;s business strategy includes entering into collaborative license, development and/or supply agreements with partners for the development and commercialization of the Company&#x2019;s products.</font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#xA0;</font></div> <div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="FONT-WEIGHT: normal"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The terms of the agreements typically include non-refundable license fees, funding of research and development, and payments based upon achievement of certain milestones. The Company adopted Accounting Standards Update 2009-13, <font style="FONT-STYLE: italic; DISPLAY: inline">Revenue Recognition,</font> in January 2011, which amends Accounting Standards Codification Subtopic 605-25, <font style="FONT-STYLE: italic; DISPLAY: inline">Multiple Element Arrangements</font> (&#x201C;ASC 605-25&#x201D;) to require the establishment of a selling price hierarchy for determining the allocable selling price of an item. Under ASC 605-25, as amended by ASU 2009-13, in order to account for an element as a separate unit of accounting, the element must have objective and reliable evidence of selling price of the undelivered elements. In general, non-refundable upfront fees and milestone payments that do not relate to other elements are recognized as revenue over the term of the arrangement as the Company completes its performance obligations.</font></font></font></div> </div>
CY2012 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2858262
CY2012 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.064 pure
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
203485
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1504707
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
8290255
CY2012 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-33995
CY2012 us-gaap Inventory Write Down
InventoryWriteDown
1310953
CY2012 us-gaap Restructuring Charges
RestructuringCharges
2537988
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-200453
CY2012 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M24D
CY2012 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14344577 shares
CY2012 us-gaap Sales Revenue Net
SalesRevenueNet
71358505
CY2012 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4271129
CY2012 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
412551
CY2012 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
412551
CY2012 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.89
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
26170313
CY2012 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13260739 shares
CY2012 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-758854
CY2012 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 Segment
CY2012 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2370318
CY2012 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
885958
CY2012 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1083838 shares
CY2012 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.350 pure
CY2012 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
326007
CY2012Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13287463 shares
CY2011Q3 us-gaap Gross Profit
GrossProfit
10361078
CY2011Q3 us-gaap Net Income Loss
NetIncomeLoss
2976518
CY2012Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
14055440
CY2012 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.05 pure
CY2012 us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
388676
CY2012 us-gaap Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends
IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends
54124 shares
CY2012 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-187777
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.5760 pure
CY2012 us-gaap Allowance For Doubtful Accounts Receivable Charge Offs
AllowanceForDoubtfulAccountsReceivableChargeOffs
135353
CY2012 us-gaap Interest Paid
InterestPaid
184881
CY2012 us-gaap Cost Of Goods Sold
CostOfGoodsSold
28988621
CY2012 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
3348336
CY2012 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-188650
CY2012 us-gaap Depreciation
Depreciation
2496749
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1151199
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
19527421
CY2012 us-gaap Revenue Recognition Sales Of Goods
RevenueRecognitionSalesOfGoods
<div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman"> Product Revenue</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; BACKGROUND-COLOR: #ffffff"> Revenues from product sales are recognized when title and risk of loss have passed to the customer, which is typically upon shipment to the customer. Amounts billed or collected prior to recognition of revenue are classified as deferred revenue. When determining whether risk of loss has transferred to customers on product sales, or if the sales price is fixed or determinable, the Company evaluates both the contractual terms and conditions of its distribution and supply agreements as well as its business practices.</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#xA0;</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="FONT-WEIGHT: normal"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; BACKGROUND-COLOR: #ffffff"> Product revenue also includes royalties. Royalty revenue is based on our distributors&#x2019; sales and recognized in the same period our distributors record their sale of products manufactured by us. On a quarterly basis we record royalty revenue based upon sales projections provided to us by our distributor customers. If necessary we adjust our estimates based upon final sales data received prior to issuing our annual audited financial statements.</font></font></font></font></div> </div>
CY2012Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.11
CY2012Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14459154 shares
CY2012Q3 us-gaap Sales Revenue Net
SalesRevenueNet
14766611
CY2012Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.12
CY2012Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
7221028
CY2012Q3 us-gaap Gross Profit
GrossProfit
6834412
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
1645250
CY2011Q4 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
17725546
CY2012 anik Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Exercises In Period Total Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsExercisesInPeriodTotalIntrinsicValue
2214516
CY2011Q4 us-gaap Sales Revenue Net
SalesRevenueNet
18444287
CY2011Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.22
CY2012 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-10269
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0064 pure
CY2012 us-gaap Tax Benefit From Stock Options Exercised1
TaxBenefitFromStockOptionsExercised1
-452471
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
131273 shares
CY2012 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-1900567
CY2012 us-gaap Net Income Loss
NetIncomeLoss
11757460
CY2012 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
452471
CY2012 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
200452
CY2012 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14728662
CY2012 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsGrantsInPeriod
204000 shares
CY2012 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsExercisesInPeriod
297855 shares
CY2012 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsForfeituresInPeriod
212749 shares
CY2012 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Vested In Period Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsVestedInPeriodFairValue
997194
CY2011Q2 us-gaap Gross Profit
GrossProfit
8758877
CY2011Q2 us-gaap Net Income Loss
NetIncomeLoss
2282641
CY2012 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2486849
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7769961
CY2012 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
5139
CY2012 us-gaap Use Of Estimates
UseOfEstimates
<div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="FONT-WEIGHT: normal"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman"> Use of Estimates</font></font></font></div> </div> <div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#xA0;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div> </div>
CY2012 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
388675
CY2012 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1420131
CY2012 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
1268442
CY2012 anik Share Based Compensation Tax Expense Benefit
ShareBasedCompensationTaxExpenseBenefit
285068
CY2012 anik Windfall Shortfall Tax Impacts To Equity
WindfallShortfallTaxImpactsToEquity
452000
CY2012 anik Allowance For Doubtful Accounts Provisions
AllowanceForDoubtfulAccountsProvisions
138339
CY2012 anik Intangible Assets Translation Adjustments
IntangibleAssetsTranslationAdjustments
-2398362
CY2012 anik Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
38329
CY2011Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13122004 shares
CY2011Q4 us-gaap Cost Of Goods Sold
CostOfGoodsSold
7128450
CY2011Q4 us-gaap Gross Profit
GrossProfit
10597096
CY2011Q4 us-gaap Net Income Loss
NetIncomeLoss
2883110
CY2012 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsExercisesInPeriodWeightedAverageExercisePrice
4.74
CY2012 anik Percentage Of Net Revenue
PercentageOfNetRevenue
1.000 pure
CY2012 anik Percentage Of Revenue Accounted By Customers
PercentageOfRevenueAccountedByCustomers
0.819 pure
CY2012 anik Net Deferred Income Tax Expense Benefit
NetDeferredIncomeTaxExpenseBenefit
-521634
CY2012Q2 us-gaap Sales Revenue Net
SalesRevenueNet
19624769
CY2012Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.28
CY2012Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13262023 shares
CY2012Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
8084226
CY2012Q2 us-gaap Gross Profit
GrossProfit
10798051
CY2012Q4 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
21459124
CY2012 anik Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Expirations In Period
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsExpirationsInPeriod
7714 shares
CY2012 anik Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Expirations In Period Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsExpirationsInPeriodWeightedAverageExercisePrice
1.68
CY2012 anik Intangible Assets Impairments And Other Adjustments
IntangibleAssetsImpairmentsAndOtherAdjustments
-1195314
CY2011Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
11060159
CY2011Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.02
CY2011Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13744710 shares
CY2011Q1 us-gaap Sales Revenue Net
SalesRevenueNet
11737679
CY2011Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2011Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12688819 shares
CY2011Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
5604562
CY2011Q1 us-gaap Gross Profit
GrossProfit
5455597
CY2011Q1 us-gaap Net Income Loss
NetIncomeLoss
324412
CY2011Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
15414681
CY2011Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.17
CY2011Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13739836 shares
CY2011Q2 us-gaap Sales Revenue Net
SalesRevenueNet
16140852
CY2011Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.18
CY2011Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12725216 shares
CY2011Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
6655804
CY2012Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
13613328
CY2012Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.14
CY2012Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14089946 shares
CY2012Q1 us-gaap Sales Revenue Net
SalesRevenueNet
14360660
CY2012Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.15
CY2012Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13162824 shares
CY2012Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
6413481
CY2012Q1 us-gaap Gross Profit
GrossProfit
7199847
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
1912119
CY2012Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
18882277
CY2012Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.26
CY2012Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14443794 shares
CY2011Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
CY2011Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13804806 shares
CY2012Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14299211 shares
CY2012Q4 us-gaap Sales Revenue Net
SalesRevenueNet
22606465
CY2012Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.33
CY2012Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13324942 shares
CY2012Q4 us-gaap Cost Of Goods Sold
CostOfGoodsSold
7269886
CY2012Q4 us-gaap Gross Profit
GrossProfit
14189238
CY2012Q4 us-gaap Net Income Loss
NetIncomeLoss
4463223

Files In Submission

Name View Source Status
0001157523-13-001397-index-headers.html Edgar Link pending
0001157523-13-001397-index.html Edgar Link pending
0001157523-13-001397.txt Edgar Link pending
0001157523-13-001397-xbrl.zip Edgar Link pending
a50585765.htm Edgar Link pending
a50585765ex21_1.htm Edgar Link pending
a50585765ex23_1.htm Edgar Link pending
a50585765ex31_1.htm Edgar Link pending
a50585765ex31_2.htm Edgar Link pending
a50585765ex32_1.htm Edgar Link pending
anik-20121231.xml Edgar Link completed
anik-20121231.xsd Edgar Link pending
anik-20121231_cal.xml Edgar Link unprocessable
anik-20121231_def.xml Edgar Link unprocessable
anik-20121231_lab.xml Edgar Link unprocessable
anik-20121231_pre.xml Edgar Link unprocessable
chart.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending